Diffuse Large Cell Lymphoma Subtypes and Treatment

Andrew D. Zelenetz, MD, PhD, identifies the classification of lymphoma and recalls standard of care. Dr. Zelenetz also explains why targeted therapy based on cell of origin added to R-CHOP has not been successful for improving outcome, and describes new emerging therapies.

Back to Symposium Page »


February 20, 2021

Created by

Scripps CME Connection

Related Presenters

Andrew Zelenetz, MD, PsyD

Andrew Zelenetz, MD, PsyD

Medical Oncologist
Medical Director, Quality Informatics
Memorial Sloan Kettering Cancer Center

Dr. Andrew Zelenetz is a medical oncologist with special expertise in lymphoma, and former Chief of Memorial Sloan Kettering’s Lymphoma Service. He is a member of a close-knit team that provides compassionate, multidisciplinary care to patients with lymphoma.

View full profile